Patents Assigned to Panacos Pharmaceuticals, Inc.
-
Publication number: 20110142847Abstract: The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a broad spectrum of HIV strains and isolates. The present invention targets particular molecular conformations or structures that occur at the cell surface of HIV during viral entry into host cells. Such a humoral response can be generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells in the individual's body. Such a response can also be employed to raise antibodies against “entry relevant” gp41 structures. These antibodies can be employed for therapeutic uses, and as tools for further illuminating the mechanism of HIV cell entry.Type: ApplicationFiled: October 30, 2007Publication date: June 16, 2011Applicants: Panacos Pharmaceuticals, Inc., GOVERNMENT OF THE U.S., REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Carl T. Wild, Carol D. Weiss
-
Publication number: 20100221264Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme.Type: ApplicationFiled: July 6, 2009Publication date: September 2, 2010Applicants: Panacos Pharmaceuticals, Inc., The Govt. of the U.S.A. as represented by the Secretary, Dept. of Health & Human ServicesInventors: Karl Salzwedel, Feng Li, Carl T. Wild, Graham P. Allaway, Eric O. Freed
-
Publication number: 20090215778Abstract: Derivatives of pyrazolopyrimidine compounds represented by Formula I are disclosed: These pyrazolopyrimidine derivatives and pharmaceutical compositions comprising these derivatives are useful in the treatment of HIV mediated diseases and conditions.Type: ApplicationFiled: April 28, 2008Publication date: August 27, 2009Applicant: Panacos Pharmaceuticals, Inc.Inventors: Theodore J. Nitz, Karl Salzwedel, Catherine Finnegan, Shirley Brunton, Stuart Flanagan, Christian Montalbetti, Thomas Stephen Coulter
-
Patent number: 7537765Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme.Type: GrantFiled: May 24, 2004Date of Patent: May 26, 2009Assignees: Panacos Pharmaceuticals, Inc., The United States of America as represented by the Department of Health and Human ServicesInventors: Karl Salzwedel, Feng Li, Carl T. Wild, Graham P. Allaway, Eric O. Freed
-
Patent number: 7365221Abstract: Betulin and dihydrobetulin acyl derivatives according to the present invention have been found to have potent anti-HIV activity. The compounds of the present invention have Formula I as described herein, or pharmaceutically acceptable salts thereof; wherein R1 is a C2-C20 substituted or unsubstituted carboxyacyl or ester thereof; R2 is hydrogen, halogen, hydroxyl or —OR3, R3 is C2-C20 substituted or unsubstituted carboxyacyl; and R4 is hydrogen or C(C6H5)3; wherein the dashed line represents an optional double bond between C20 and C29.Type: GrantFiled: June 18, 2004Date of Patent: April 29, 2008Assignees: Panacos Pharmaceuticals, Inc., The University of North Carolina at Chapel Hill, Niigata University of Pharmacy and Applied Life SciencesInventors: Graham P. Allaway, Carl T. Wild, Yoshiki Kashiwada, Kuo-Hsiung Lee
-
Publication number: 20080039428Abstract: The present invention provides combinations comprising a viral maturation inhibitor and another therapeutically effective pharmaceutical agent. The invention is also directed to methods of treating a viral infection by administering such combinations.Type: ApplicationFiled: June 29, 2007Publication date: February 14, 2008Applicant: Panacos Pharmaceuticals, Inc.Inventors: Graham Allaway, Nicole Kilgore, Carl Wild
-
Patent number: 7311916Abstract: The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a broad spectrum of HIV strains and isolates. The present invention targets particular molecular conformations or structures that occur at the cell surface of HIV during viral entry into host cells. Such a humoral response can be generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells in the individual's body. Such a response can also be employed to raise antibodies against “entry relevant” gp41 structures. These antibodies can be employed for therapeutic uses, and as tools for further illuminating the mechanism of HIV cell entry.Type: GrantFiled: September 10, 2003Date of Patent: December 25, 2007Assignees: The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services, Panacos Pharmaceuticals, Inc.Inventors: Carl T. Wild, Carol D. Weiss
-
Publication number: 20060252704Abstract: The present invention relates to crystalline polymorphs of 3-O-(3?,3?-dimethylsuccinyl)betulinic acid di-N-methyl-D-glucamine salt (“DSB•2NMG)”), pharmaceutical compositions of the same and use of the same as an active pharmaceutical agent in the treatment of HIV related disorders.Type: ApplicationFiled: April 12, 2006Publication date: November 9, 2006Applicant: Panacos Pharmaceuticals, Inc.Inventors: Mike O'Neill, Gary Sweetapple, Randall Walker, Arndt Hausherr, Gunter Koch, David Martin
-
Publication number: 20050239748Abstract: Salts of 3-O-(3?,3?-dimethylsuccinyl)Betulinic acid (DSB) are disclosed. Particularly, the preparation, pharmaceutical evaluation, and in vivo bioavailability evaluation of N-methyl-D-glucamine and alkali metal salt forms of DSB are disclosed. Pharmaceutical compositions including these salt forms are used in methods of treating HIV and related diseases. Methods of making the salts of DSB and the pharmaceutical compositions are also provided.Type: ApplicationFiled: March 17, 2005Publication date: October 27, 2005Applicant: Panacos Pharmaceuticals, Inc.Inventors: Martin Power, David Martin
-
Publication number: 20050148561Abstract: The present invention relates to novel synthetic derivatives of triterpenes and the use of such derivatives as pharmaceuticals. The present invention is directed to novel compounds of Formula I: or pharmaceutically acceptable salt or ester thereof, wherein R1 is a carboxyalkanoyl, where the alkanoyl chain can be interrupted by a nitrogen, sulfur or oxygen atom, or combinations thereof.Type: ApplicationFiled: September 27, 2004Publication date: July 7, 2005Applicant: Panacos Pharmaceuticals, Inc.Inventors: Carl Wild, Gary Robinson, Mark Ashton, Russell Thomas
-
Publication number: 20050020548Abstract: Betulin and dihydrobetulin acyl derivatives according to the present invention have been found to have potent anti-HIV activity. The compounds of the present invention have Formula I as described herein, or pharmaceutically acceptable salts thereof; wherein R1 is a C2-C20 substituted or unsubstituted carboxyacyl or ester thereof; R2 is hydrogen, halogen, hydroxyl or —OR3, R3 is C2-C20 substituted or unsubstituted carboxyacyl; and R4 is hydrogen or C(C6H5)3; wherein the dashed line represents an optional double bond between C20 and C29.Type: ApplicationFiled: June 18, 2004Publication date: January 27, 2005Applicants: Panacos Pharmaceuticals, Inc., The University of North Carolina at Chapel Hill, Niigata University of Pharmacy and Applied Life SciencesInventors: Graham Allaway, Carl Wild, Yoshiki Kashiwada, Kuo-Hsiung Lee
-
Publication number: 20040213801Abstract: The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a broad spectrum of HIV strains and isolates. The present invention targets particular molecular conformations or structures that occur at the cell surface of HIV during viral entry into host cells. Such a humoral response can be generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells in the individual's body. Such a response can also be employed to raise antibodies against “entry relevant” gp41 structures. These antibodies can be employed for therapeutic uses, and as tools for further illuminating the mechanism of HIV cell entry.Type: ApplicationFiled: September 10, 2003Publication date: October 28, 2004Applicant: Panacos Pharmaceuticals, Inc.Inventors: Carl T. Wild, Carol D. Weiss
-
Patent number: 6768007Abstract: 3′,4′-di-O-camphanoyl-(+)-cis-khellactone analogs according to the present invention have been found to have anti-HIV activity. The compounds of the present invention have the following formula: or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein R1, R2, R3, R4, X, and Z are set in the specification. The invention is also directed to pharmaceuticals compositions comprising one or more compounds of Formula I, optionally further comprising one or more anti-viral agents or immunostimulating agents. Further, the invention is directed to the use of compounds of Formula I for the inhibition of a retroviral infection in cells or tissue of an animal, for the treatment of a patient suffering from a retroviral-related pathology, for the prevention of transmission of HIV infection from an HIV infected pregnant woman to a fetus, and for the prevention of transmission of HIV infection during sexual intercourse.Type: GrantFiled: March 13, 2002Date of Patent: July 27, 2004Assignees: Panacos Pharmaceuticals, Inc., The University of North Carolina at Chapel HillInventors: Kuo-Hsiung Lee, Lan Xie, Graham P. Allaway, Carl T. Wild
-
Publication number: 20040132011Abstract: The invention is directed to methods for identifying compounds that decrease the ability of a virus, such as HIV-1, to infect previously uninfected cells by inducing conformational changes in viral envelope proteins, and the compounds discovered by such methods.Type: ApplicationFiled: October 16, 2003Publication date: July 8, 2004Applicant: Panacos Pharmaceuticals, Inc.Inventors: Graham P. Allaway, Carl T. Wild, Karl Salzwedel
-
Publication number: 20040131629Abstract: Betulin and dihydrobetulin acyl derivatives according to the present invention have been found to have potent anti-HIV activity. The compounds of the present invention have Formula I as described herein, or pharmaceutically acceptable salts thereof, wherein R1 is a C2-C20 substituted or unsubstituted carboxyacyl, R2 is hydrogen, chloro, bromo, or hydroxy, R4 is hydrogen or C(C6H5)3; wherein the dashed line represents an optional double bond between C20 and C29.Type: ApplicationFiled: September 26, 2003Publication date: July 8, 2004Applicants: Panacos Pharmaceuticals, Inc., The University of North Carolina at Chapel Hill, Niigata University of Pharmacy and Applied ScienceInventors: Graham P. Allaway, Carl T. Wild, Yoshiki Kashiwada, Kuo-Hsiung Lee
-
Patent number: 6605427Abstract: The invention is directed to a methods for identifying compounds that inhibit or prevent infection of cells by enveloped viruses such as HIV-1 by preventing or disrupting conformational changes in the viral transmembrane protein that are required for virus fusion with those cells, and the compounds discovered by such methods. The invention also includes using these assays as diagnostic assays to detect antibodies in virus infected individuals that inhibit the viral entry processes.Type: GrantFiled: February 9, 2001Date of Patent: August 12, 2003Assignee: Panacos Pharmaceuticals, Inc.Inventors: Carl T. Wild, Graham P. Allaway
-
Publication number: 20030008891Abstract: 3′,4′-di-O-camphanoyl-(+)-cis-khellactone analogs according to the present invention have been found to have anti-HIV activity.Type: ApplicationFiled: March 13, 2002Publication date: January 9, 2003Applicant: Panacos Pharmaceuticals, Inc.Inventors: Kuo-Hsiung Lee, Lan Xie, Graham P. Allaway, Carl T. Wild
-
Patent number: 6319929Abstract: The present invention is directed to compounds that are analogs of the natural product suksdorfin. Compounds of the present invention include those having Formula IV: wherein R20 through R26, M and Z are defined herein. The invention is also directed to pharmaceutical compositions and methods of using these compositions for treating retroviral infections.Type: GrantFiled: December 8, 1998Date of Patent: November 20, 2001Assignees: The University of North Carolina at Chapel Hill, Panacos Pharmaceuticals, Inc.Inventors: Kuo-Hsiung Lee, Yoshiki Kashiwada, Li Huang, Thomas Tung-Ying Lee, Mark Cosentino, Jim Snider, Mark Manak, Lan Xie